Significance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) for the Monitoring of Treatment Response to Cyclosporine in Patients with Psoriasis

doi:10.3390/life13091873

. 2023 Sep 6;13(9):1873.

doi: 10.3390/life13091873.

Significance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) for the Monitoring of Treatment Response to Cyclosporine in Patients with Psoriasis

Aleksandra Frątczak¹, Bartosz Miziołek¹, Agnieszka Łupicka-Słowik², Marcin Sieńczyk², Karina Polak¹, Beata Bergler-Czop¹

Affiliations

¹ Department of Dermatology, School of Medicine in Katowice, Medical University of Silesia, 20/24 Francuska St., 40-067 Katowice, Poland.
² Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.

PMID: 37763277
PMCID: PMC10532527
DOI: 10.3390/life13091873

Significance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) for the Monitoring of Treatment Response to Cyclosporine in Patients with Psoriasis

Aleksandra Frątczak et al. Life (Basel). 2023.

. 2023 Sep 6;13(9):1873.

doi: 10.3390/life13091873.

Authors

Aleksandra Frątczak¹, Bartosz Miziołek¹, Agnieszka Łupicka-Słowik², Marcin Sieńczyk², Karina Polak¹, Beata Bergler-Czop¹

Affiliations

¹ Department of Dermatology, School of Medicine in Katowice, Medical University of Silesia, 20/24 Francuska St., 40-067 Katowice, Poland.
² Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.

PMID: 37763277
PMCID: PMC10532527
DOI: 10.3390/life13091873

Abstract

Neutrophil gelatinase-associated lipocalin (NGAL) may promote development of inflammation in psoriasis, whereas proprotein convertase subtilisin/kexin type 9 (PCSK9) may account for dyslipidemia in some psoriatic patients. The aim of the study was to analyze the influence of cyclosporine therapy on serum levels of NGAL and PCSK9 in patients with psoriasis vulgaris.

Methods: Serum samples were obtained before and after three months cyclosporine therapy. Patients were grouped into responders and non-responders to cyclosporine depending on whether they achieved at least 50% reduction of Psoriatic Activity Score Index (PASI), or not. Serum levels of PCSK9 and NGAL were assayed using commercially available ELISA tests. Lipid levels were measured with an enzymatic method.

Results: There were 40 patients enrolled. A significant decrease in serum NGAL level was seen in cyclosporine responders. No similar dependance was found for PCSK9. Serum PCSK9 concentration correlated with total cholesterol (TChol) and LDL at baseline and after three month treatment.

Conclusions: Cyclosporine therapy contributes to the reduction of the NGAL serum but not the PCSK9 concentration. Correlation between the PCSK9 serum level and TChol as well as LDL concentration may help to understand drug induced dyslipidemia after cyclosporine.

Keywords: NGAL; PCSK9; cyclosporine; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Cited by

Causal effects of lipid-lowering drugs on skin diseases: a two-sample Mendelian randomization study.
Liu Y, Liu H, Bian Q. Liu Y, et al. Front Med (Lausanne). 2024 Sep 25;11:1396036. doi: 10.3389/fmed.2024.1396036. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39386745 Free PMC article.
Genetically proxied PCSK9 inhibition is associated with reduced psoriatic arthritis risk.
Li J, Li J, Lin C, Zhou J, Wang J, Wang F, Li H, Zhou Z. Li J, et al. Inflamm Res. 2024 Mar;73(3):475-484. doi: 10.1007/s00011-024-01850-3. Epub 2024 Feb 11. Inflamm Res. 2024. PMID: 38341813 Free PMC article.
Is there still a place for neutrophil gelatinase-associated lipocalin to serve as a biomarker in psoriasis?
Frątczak A, Łupicka-Słowik A, Sieñczyk M, Polak K, Bergler-Czop B, Miziołek B. Frątczak A, et al. Postepy Dermatol Alergol. 2024 Dec;41(6):571-576. doi: 10.5114/ada.2024.142572. Epub 2024 Aug 29. Postepy Dermatol Alergol. 2024. PMID: 39877113 Free PMC article.

References

1. Shao S., Cao T., Jin L., Li B., Fang H., Zhang J., Zhang Y., Hu J., Wang G. Increased Lipocalin-2 Contributes to the Pathogenesis of Psoriasis by Modulating Neutrophil Chemotaxis and Cytokine Secretion. J. Investig. Dermatol. 2016;136:1418–1428. doi: 10.1016/j.jid.2016.03.002. - DOI - PubMed
1. Hau C.S., Kanda N., Tada Y., Shibata S., Uozaki H., Fukusato T., Sato S., Watanabe S. Lipocalin-2 exacerbates psoriasiform skin inflammation by augmenting T-helper 17 response. J. Dermatol. 2016;43:785–794. doi: 10.1111/1346-8138.13227. - DOI - PubMed
1. Frątczak A., Polak K., Szczepanek M., Lis-Święty A. The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus. Postep. Dermatol. Alergol. 2022;39:645–650. doi: 10.5114/ada.2022.118919. - DOI - PMC - PubMed
1. Luan C., Chen X., Zhu Y., Osland J.M., Gerber S.D., Dodds M., Hu Y., Chen M., Yuan R. Potentiation of Psoriasis-Like Inflammation by PCSK9. J. Investig. Dermatol. 2019;139:859–867. doi: 10.1016/j.jid.2018.07.046. - DOI - PMC - PubMed
1. Merleev A., Ji-Xu A., Toussi A., Tsoi L.C., Le S.T., Luxardi G., Xing X., Wasikowski R., Liakos W., Brüggen M.C., et al. Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related to IL36G. JCI Insight. 2022;7:e141193. doi: 10.1172/jci.insight.141193. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Shao S., Cao T., Jin L., Li B., Fang H., Zhang J., Zhang Y., Hu J., Wang G. Increased Lipocalin-2 Contributes to the Pathogenesis of Psoriasis by Modulating Neutrophil Chemotaxis and Cytokine Secretion. J. Investig. Dermatol. 2016;136:1418–1428. doi: 10.1016/j.jid.2016.03.002. - DOI - PubMed

[2] Shao S., Cao T., Jin L., Li B., Fang H., Zhang J., Zhang Y., Hu J., Wang G. Increased Lipocalin-2 Contributes to the Pathogenesis of Psoriasis by Modulating Neutrophil Chemotaxis and Cytokine Secretion. J. Investig. Dermatol. 2016;136:1418–1428. doi: 10.1016/j.jid.2016.03.002. - DOI - PubMed

[3] Hau C.S., Kanda N., Tada Y., Shibata S., Uozaki H., Fukusato T., Sato S., Watanabe S. Lipocalin-2 exacerbates psoriasiform skin inflammation by augmenting T-helper 17 response. J. Dermatol. 2016;43:785–794. doi: 10.1111/1346-8138.13227. - DOI - PubMed

[4] Hau C.S., Kanda N., Tada Y., Shibata S., Uozaki H., Fukusato T., Sato S., Watanabe S. Lipocalin-2 exacerbates psoriasiform skin inflammation by augmenting T-helper 17 response. J. Dermatol. 2016;43:785–794. doi: 10.1111/1346-8138.13227. - DOI - PubMed

[5] Frątczak A., Polak K., Szczepanek M., Lis-Święty A. The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus. Postep. Dermatol. Alergol. 2022;39:645–650. doi: 10.5114/ada.2022.118919. - DOI - PMC - PubMed

[6] Frątczak A., Polak K., Szczepanek M., Lis-Święty A. The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus. Postep. Dermatol. Alergol. 2022;39:645–650. doi: 10.5114/ada.2022.118919. - DOI - PMC - PubMed

[7] Luan C., Chen X., Zhu Y., Osland J.M., Gerber S.D., Dodds M., Hu Y., Chen M., Yuan R. Potentiation of Psoriasis-Like Inflammation by PCSK9. J. Investig. Dermatol. 2019;139:859–867. doi: 10.1016/j.jid.2018.07.046. - DOI - PMC - PubMed

[8] Luan C., Chen X., Zhu Y., Osland J.M., Gerber S.D., Dodds M., Hu Y., Chen M., Yuan R. Potentiation of Psoriasis-Like Inflammation by PCSK9. J. Investig. Dermatol. 2019;139:859–867. doi: 10.1016/j.jid.2018.07.046. - DOI - PMC - PubMed

[9] Merleev A., Ji-Xu A., Toussi A., Tsoi L.C., Le S.T., Luxardi G., Xing X., Wasikowski R., Liakos W., Brüggen M.C., et al. Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related to IL36G. JCI Insight. 2022;7:e141193. doi: 10.1172/jci.insight.141193. - DOI - PMC - PubMed

[10] Merleev A., Ji-Xu A., Toussi A., Tsoi L.C., Le S.T., Luxardi G., Xing X., Wasikowski R., Liakos W., Brüggen M.C., et al. Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related to IL36G. JCI Insight. 2022;7:e141193. doi: 10.1172/jci.insight.141193. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Significance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) for the Monitoring of Treatment Response to Cyclosporine in Patients with Psoriasis

Affiliations

Significance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) for the Monitoring of Treatment Response to Cyclosporine in Patients with Psoriasis

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous